Medical isotope firm Shine Medical Technologies has secured $50 million in financing with funds managed by Oaktree Capital Management of Los Angeles.
The funds will support Shine's ongoing construction of a new production facility and its commercialization of the diagnostic and therapeutic isotopes molybdenum-99 (Mo-99) and lutetium-177 (Lu-177).
Shine expects construction of the new facility to be completed in 2021 and isotope production to begin in 2022, the company said.